Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 3Phase 1 2Phase 2/3 1Phase 1/2 1

Status

Completed 65Terminated 25Unknown 12Recruiting 12Withdrawn 4Active not recruiting 1

Sponsor Class

OTHER 2NIH 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Uterine Cervical Dysplasia 1Squamous Intraepithelial Lesions 1Colorectal Neoplasms 1Carcinoma, Basal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 61Radiotherapy 55Gemcitabine 51Paclitaxel 49Cyclophosphamide 48Cisplatin 48Carboplatin 45Dexamethasone 37Bevacizumab 37Nivolumab 35Fluorouracil 34Docetaxel 34Oxaliplatin 33durvalumab 32Rituximab 28Magnetic Resonance Spectroscopy 28Leucovorin 28Drug Therapy 25Pemetrexed 24Doxorubicin 24Capecitabine 24atezolizumab 22Radiation 20Cytarabine 20Radiosurgery 19Prednisone 19Etoposide 19Irinotecan 17Bortezomib 17Cetuximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × Celecoxib × Clear all
NCT03185871 2019-11-15

Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses

University of Wisconsin, Madison

Phase 2 Withdrawn
Breast

Breast Neoplasms

NCT02615574 2017-09-26

A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer

University of Pittsburgh

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

NCT00072540 2013-11-08

S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix

SWOG Cancer Research Network

Phase 2 Withdrawn
Gynecologic

Squamous Intraepithelial Lesions, Uterine Cervical Dysplasia

NCT00025051 2013-03-22

Celecoxib in Preventing Skin Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn
Dermatologic

Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡